Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne

ClinicalTrials.gov ID: NCT00656981

Public ClinicalTrials.gov record NCT00656981. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety & Efficacy of Oral Contraceptive Prep., Containing Drospirenone 3 mg/Ethinyl Estradiol 20 Mcg for 6 Treatment Cycles in Women With Moderate Acne Vulgaris

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles

Study identification

NCT ID
NCT00656981
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bayer
Industry
Enrollment
541 participants

Conditions and interventions

Eligibility (public fields only)

Age range
14 Years to 45 Years
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2003 (Type not available)
Primary completion
Not listed
Completion
Jun 2004 (Actual)
Last update posted
Dec 30, 2014

2003 – 2004

United States locations

U.S. sites
22
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Not listed Mobile Alabama 36608 —
Not listed Kingman Arizona 86401 —
Not listed Encino California 91436 —
Not listed San Diego California 92103 —
Not listed San Diego California 92123 —
Not listed Westlake Village California 91361 —
Not listed Castle Rock Colorado 80108 —
Not listed Denver Colorado 80246 —
Not listed Palm Springs Florida 33461 —
Not listed St. Petersburg Florida 33702 —
Not listed Venice Florida 34285 —
Not listed Boise Idaho 83704 —
Not listed Shawnee Kansas 66203 —
Not listed Louisville Kentucky 40217 —
Not listed Fridley Minnesota 55432 —
Not listed East Steauket New York 11733 —
Not listed New York New York 10022 —
Not listed Medford Oregon 97504 —
Not listed Portland Oregon 97223-6683 —
Not listed Byran Texas 77801 —
Not listed Arlington Virginia 22203 —
Not listed Seattle Washington 98105 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00656981, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 30, 2014 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00656981 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →